Hemostemix Inc · TSXV:HEM
Hemostemix — Investor Presentation (2026)
17 slides from Hemostemix's investor presentation, Nov 4, 2026
Slide 1: VesCell: Investor Presentation Q4 2026
I N V E S T O R P R E S E N TAT I O N · Q4 2026 VesCell™ The patient’s own cells, educated to restore circulation Twenty years in the making. Commercially approved by LARTA. Thomas Smeenk, CEO tsmeenk@hemostemix.com +1 905 580 4170 TSXV: HEM OTCQB: HMTXF FSE: 2VF0 Hemostemix Inc. · Investor presenta
Slide 2: The Bahamas: The World's Gateway to Regulated Stem Cell Therapy
The Bahamas: The World’s Gateway to Regulated Stem Cell Therapy Hemostemix has received full LARTA and ~20 ethics approval for its commercial treatment for angina, vascular dementia and pain. Our commercial model brings eligible patients from around the Years of investment world to The Bahamas for t
Slide 3: How VesCell's Mechanism of Action rebuilds blood flow
How VesCell's Mechanism of Action rebuilds blood flow Injury calls for help 1 Restricted flow starves tissue of oxygen. The injured tissue signals for help. VesCell homes in 2 Cells follow the signals to the site and release growth signals of their own. Flow may return 3 New branching microvessels m
Slide 4: Saving a limb is saving a life
Saving a limb is saving a life Phase II follow-up Universities of Toronto and British Columbia reported ulcer healing in 83% of patients followed for up to 4.5 years, with cessation of pain and no major amputation or mortality reported in that follow-up group. Ulcer size decreased significantly by 3
Slide 5: Clinically relevant results
Clinically relevant results Published findings by study. NR = not reported; (1) to (15) number the outcomes in each row and match the p values in the last column. Study Indication / population Study n Clinically relevant findings p values, in outcome order Mutirangura et al., No-option CLI; unsuitab
Slide 6: Illustrative annual HNW demand at 1%, 2% and 3% uptake
Illustrative annual HNW demand at 1%, 2% and 3% uptake Angina, vascular dementia, pain, ischemic and dilated cardiomyopathy, congestive heart failure, critical limb ischemia and longevity represent the clinical opportunity. HNW population assumption Low 1% / year Base 2% / year High 3% / year No-opt
Slide 7: Landing the milestones
Landing the milestones Oct 7, 2026 Q4 2026 Q4 2026 Apr 1, 2027 Full LARTA and ethics Financing Longevity protocol First paid treatments approval filing Bahamas program for angina, CAD $3M gross Management target for a second 13 treatments in Q2 2027 in the vascular dementia and pain protocol model T
Slide 8: Business model: paid treatment revenue to Hemostemix
Business model: paid treatment revenue to Hemostemix Equity funds generate revenue and patient data through patient recruitment, treatment and structured follow-up Per completed treatment USD Model treatment Cash receipt to Hemostemix 50,000 Illustrative self-pay collection Contract manufacturing (1
Slide 9: The operating plan reaches treatments/week in Q4 2029
The operating plan reaches 14 treatments/week in Q4 2029 Q4 2026–Q1 2027: patient recruitment and sales activity. Treatments begin April 1, 2027 in the model. 16 14 14 12 12 10 Treatments per week 10 8 6 5 5 4 4 4 3 3 2 2 1 0 0 0 Q4 ’26 Q1 ’27 Q2 ’27 Q3 ’27 Q4 ’27 Q1 ’28 Q2 ’28 Q3 ’28 Q4 ’28 Q1 ’29
Slide 10: Quarterly cash flow through Q4 2029
Quarterly cash flow through Q4 2029 April 1, 2027 treatment start. Quarterly amounts in US$000. Illustrative ending cash: US$11.12M. Quarter Treatments Receipts Direct costs Fixed / sales Operating CF Net equity Ending cash Q4 2026 0 0.0 0.0 (457.5) (457.5) 1,971.4 1,513.9 Q1 2027 0 0.0 0.0 (350.0)
Slide 11: We earned trust, and trust built a following
We earned trust, and trust built a following 5 750 1.39M doctor-led webinars enrolled in or requested the vascular dementia patients replay of our vascular in our demand model dementia webinar Respected doctors explained Sufferers and their The size of the community the science to an audience of car
Slide 12: Longevity Regenerative Therapy Act 2024 enables user-pay
Longevity Regenerative Therapy Act 2024 enables user-pay. T H E U S U A L PAT H O U R PAT H U N D E R L A R TA Raise risk capital to fund Cashflow funds regulatory advancement · Valuation cliffs based on Phase I, II, III outcomes · A phase I clinical trial treatment paid by the user · Regulators con
Slide 13: We have the team, the approvals and the agreements
We have the team, the approvals and the agreements The team The approvals The agreements · Thomas Smeenk, CEO · Full LARTA and ethics approval, · Doctors Hospital fixed-price October 7, 2026 treatment arrangement · Dr. Ina Sarel, Chief Scientific · Bahamas program for angina, · Cardiologist for hear
Slide 14: CAD $3M: Join Insiders who invested $10.5M since March 2020
Join Insiders who invested $10.5M since March 2020 CAD $0.05 per unit CAD $3M One financing Each unit comprises: We expect valuation to increase as 1 common share treatments start and outcomes are published. Today's valuation is ½ warrant exceptionally well priced. Each whole warrant exercisable at
Slide 15: Pro forma capitalization
Pro forma capitalization As at October 31, 2026. All prices in Canadian dollars. Shares / underlying Exercise / conversion % of fully diluted Security % of basic shares shares price shares¹ Common shares issued and outstanding 211,441,448 — 100.0% 68.7% C$0.150 weighted Share-purchase and finder war
Slide 16: Pro forma warrant schedule
Pro forma warrant schedule As at October 31, 2026. All amounts in Canadian dollars. Expiry date Warrant type Warrants outstanding Exercise price Maximum exercise proceeds November 29, 2026 Investor 16,665,160 C$0.12 C$1,999,819.20 November 29, 2026 Broker 128,413 C$0.05 C$6,420.65 April 25, 2027 Inv
Slide 17: Forward-looking information and limitations
Forward-looking information and limitations This presentation describes a proposed financing and an illustrative operating scenario. No binding financing commitment, completed closing or achieved patient milestone is represented. Definitive pricing, subscriptions, closing conditions, finder eligibil